Mochi Health Lawsuit, a big drug company, has filed a lawsuit against Mochi Health—a telehealth company—and several others. The lawsuit began on April 23, 2025, and targets Mochi Health along with Fella & Delilah Health, Willow Health, and Henry Meds.
ALSO READ : New Century Health
Eli Lilly alleges these companies are selling compounded versions of its popular drugs Mounjaro® and Zepbound®—medications used for treating diabetes and obesity—without proper approval.
Why Eli Lilly Is Suing
Selling Knockoffs
Mochi Health reportedly sells versions of tirzepatide (the active ingredient in Lilly’s drugs) mixed with additives like vitamins or amino acids. These mixtures are meant to appear different but are essentially copycats.
False Advertising
Lilly claims these companies falsely advertise their service as “personalized,” safe, or FDA-approved—claims that do not apply to untested compounded drugs.
Unsafe Practices
Mochi Health made mass changes to patient prescriptions multiple times in just eight months, altering doses and additives based on business decisions—not medical reasons.
Misleading Branding
Mochi Health used Lilly’s drug names, images, and trial data (SURMOUNT, SURPASS) to promote their products—even though their compounded versions weren’t studied in those trials.
Pharmacy Safety Issues
Mochi’s pharmacy partner, Aequita Pharmacy, was forced to stop production by Washington regulators for practices that risked patient safety—like using untrained staff for sterile compounding.
Mochi Health Responds
Mochi Health issued a public statement affirming its commitment to affordable, evidence-based obesity care. They say the lawsuit is an attack on access, not safety or legality. They promise to maintain access to care, work with partners to fulfill orders, and continue serving patients.
What This Means for Patients
- Risk to Safety: Compounded drugs are not approved or tested by the FDA, especially when altered with additives. This raises serious safety concerns.
- False Sense of Trust: Patients might believe they are getting FDA-approved drugs when they really aren’t.
- Access Issues: If Mochi Health is forced to stop selling compounded versions, some patients may lose access—unless affordable, approved alternatives are available.
- Legal Clarity: The lawsuit could set a clear rule: compounding is for individual medical needs—not mass-market alternatives.
Conclusion
The Mochi Health lawsuit highlights a major clash:
- On one side is affordable access—patients seeking lower prices.
- On the other is patient safety and legality—ensuring drugs are tested and approved.
The court’s decision may reshape how compounded medications are treated in telehealth, influencing both regulation and patient access.
FAQs
What is a compounded drug?
A compounded drug is made by mixing ingredients in a pharmacy to meet individual patient needs. These are not official, brand-name drugs.
Why is Lilly suing Mochi Health now?
Because the FDA shortage for tirzepatide has ended, any non-personalized compounding is now illegal.
Did Mochi really switch doses without telling patients?
Yes. In just eight months, they changed additives and dosages multiple times, based on business—not medical—reasons.
Are Mochi’s drugs approved like Mounjaro® or Zepbound®?
No. They are untested, unapproved compounds. Mochi used images and trial data to suggest otherwise—which Lilly says is misleading.
Was Mochi’s pharmacy partner unsafe?
Yes. Aequita Pharmacy was shut down in March 2025 by Washington regulators for unsafe compounding practices.
Will this lawsuit stop my treatment?
It’s unclear. Mochi says they’ll still provide care through partners, but the court’s final decision could affect availability.